Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of the 4Kscore in EPIC: Letter.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same author

Transcriptome-wide association studies implicate RCC1 and PHACTR4 in prostate cancer survival.

European journal of human genetics : EJHG·2026
Same author

Estimating the Effect of Finasteride on Kallikrein Marker Levels in Blood and the Use of Converted Markers in the Four-Kallikrein Model.

European urology focus·2026
Same author

Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT Study.

European urology·2026
Same author

Five things you need to know about prostate cancer diagnostic tests.

Asian journal of urology·2025
Same author

MicroRNA-379 Modulates Prostate-Specific Antigen Expression Through Targeting the Androgen Receptor in Prostate Cancer.

Cancers·2025

Related Experiment Video

Updated: Jun 27, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Screening for prostate cancer: an update.

Shahrokh F Shariat1, Peter T Scardino, Hans Lilja

  • 1Department of Surgery (Urology Service), Clinical Laboratories, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

The Canadian Journal of Urology
|December 3, 2008
PubMed
Summary
This summary is machine-generated.

Total prostate-specific antigen (tPSA) testing significantly aids prostate cancer detection. Understanding tPSA variability and using it with other factors improves risk assessment for screening and biopsy decisions.

More Related Videos

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Related Experiment Videos

Last Updated: Jun 27, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Area of Science:

  • Urology
  • Oncology
  • Biochemistry

Background:

  • Total prostate-specific antigen (tPSA) testing revolutionized prostate cancer detection and management.
  • Understanding tPSA variability (analytical and biological) is crucial for accurate interpretation.
  • No single tPSA cutoff reliably distinguishes high-risk from low-risk prostate cancer.

Purpose of the Study:

  • To review advancements in prostate cancer screening, focusing on tPSA.
  • To highlight the role of tPSA in risk stratification and shared decision-making for biopsies.
  • To explore the potential of early tPSA measurements and novel biomarkers.

Main Methods:

  • Review of existing literature on tPSA testing and prostate cancer screening.
  • Analysis of factors influencing tPSA variability.
  • Discussion of tPSA velocity, free PSA, and hK2 in prostate cancer detection and prognosis.

Main Results:

  • tPSA levels exhibit significant analytical and biological variability.
  • tPSA, combined with clinical factors, aids in estimating cancer risk and guiding biopsy decisions.
  • Elevated tPSA years before diagnosis suggests a long carcinogenic process; early measurements may aid risk stratification.
  • tPSA velocity shows limited value in screening but potential post-diagnosis.
  • Free PSA and hK2 show promise but require further clinical validation.

Conclusions:

  • tPSA is a valuable tool in prostate cancer screening, but its interpretation requires considering individual risk factors and inherent variability.
  • Enhancing tPSA specificity is key to reducing unnecessary biopsies.
  • Further research on early tPSA use and novel biomarkers like free PSA and hK2 is warranted for improved prostate cancer management.